Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond

Future Oncology

Volumn 10, Issue 9, 2014, Pages 1679-1694

  Mikropoulos, Christos ^a   Goh, Chee ^a   Leongamornlert, Daniel ^a   Kote Jarai, Zsofia ^a   Eeles, Rosalind ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

biomarkers; fine mapping; imputation; single nucleotide polymorphisms; targeted screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER SCREENING; CANCER SUSCEPTIBILITY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; HIGH RISK POPULATION; HUMAN; MORBIDITY; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM; GENETICS; MALE; PENETRANCE; PROSTATIC NEOPLASMS; TRANSLATIONAL RESEARCH; TUMOR GENE;

GENES, NEOPLASM; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; PENETRANCE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RISK FACTORS; TRANSLATIONAL MEDICAL RESEARCH; TUMOR MARKERS, BIOLOGICAL;

EID: 84906570444     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.72     Document Type: Review

References (125)

1. Cancer Research UK 2013: cancer incidence for common cancers. www.cancerresearchuk.org/cancer-info/cancerstats/incidence/commoncancers/ uk-cancer-incidence-statistics-for-common-cancers
2. Isaacs WB. Molecular genetics of prostate cancer. Cancer Surv. 25, 357-379 (1995
3. Brawley OW. Prostate cancer and black men. Semin. Urol. Oncol. 16(4), 184-186 (1998
4. Eeles RA. Genetic predisposition to prostate cancer. Prostate Cancer Prostatic Dis. 2(1), 9-15 (1999
5. Page WF, Braun MM, Caporaso NE. Ascertainment of mortality in the U.S. veteran population: World War II veteran twins. Mil. Med. 160(7), 351-355 (1995
6. Gronberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in a twin population. J. Urol. 152(5 Pt 1), 1484-1487; (1994
7. Stanford JL, Ostrander EA. Familial prostate cancer. Epidemiol. Rev. 23(1), 19-23 (2001
8. Ferlay J SH, Bray F, Forman D, Mathers C et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127(12), 2893-2917 (2008
9. Karayi MK, Neal DE, Markham AF. Current status of linkage studies in hereditary prostate cancer. BJU Int. 86(6), 659-669 (2000
10. Xu J, Dimitrov L, Chang BL et al. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics. Am. J. Hum. Genet. 77(2), 219-229 (2005
11. Amundadottir LT, Sulem P, Gudmundsson J et al. A common variant associated with prostate cancer in European and African populations. Nat. Genet. 38(6), 652-658 (2006
12. Ewing CM, Ray AM, Lange EM et al. Germline mutations in HOXB13 and prostate-cancer risk. N. Engl. J. Med. 366(2), 141-149 (2012). •• Important study explaining the impact of HOXB13 mutation on prostate cancer (PrCa) risk
13. Eeles RA, Kote-Jarai Z, Al Olama AA et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat. Genet. 41(10), 1116-1121 (2009
14. Abecasis GR. An integrated map of genetic variation from 1,092 human genomes. Nat. Rev. Urol. 491(7422), 56-65 (2012
15. The 1000 Genomes Project. www.1000genomes.org
16. Spencer Cc SZ, Donnelly P, Marchini J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet. 5(5), e1000477 (2009
17. Goh CL, Schumacher FR, Easton D et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J. Intern. Med. 271(4), 353-365 (2012
18. Agalliu I, Karlins E, Kwon EM et al. Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer. Br. J. Cancer 97(6), 826-831 (2007
19. Rafnar T, Sulem P, Stacey SN et al. Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. Nat. Genet. 41(2), 221-227 (2009
20. Gudmundsson J, Sulem P, Rafnar T et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat. Genet. 40(3), 281-283 (2008
21. Kote-Jarai Z, Olama AA, Giles GG et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat. Genet. 43(8), 785-791 (2011
22. Thomas G, Jacobs KB, Yeager M et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat. Genet. 40(3), 310-315 (2008
23. Yeager M, Orr N, Hayes RB et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat. Genet. 39(5), 645-649 (2007
24. Gudmundsson J, Sulem P, Manolescu A et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet. 39(5), 631-637 (2007
25. Al Olama AA, Kote-Jarai Z, Giles GG et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat. Genet. 41(10), 1058-1060 (2009
26. Xu J, Mo Z, Ye D et al. Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4. Nat. Genet. 44(11), 1231-1235 (2012
27. Duggan D, Zheng SL, Knowlton M et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J. Natl Cancer Inst. 99(24), 1836-1844 (2007
28. Eeles RA, Kote-Jarai Z, Giles GG et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat. Genet. 40(3), 316-321 (2008
29. Akamatsu S, Takata R, Haiman CA et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat. Genet. 44(4), 426-429, S421 (2012
30. Eeles RA, Olama AA, Benlloch S et al. Identification of new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat. Genet. 45(4), 385-391, 391e381-382 (2013
31. Schumacher FR, Berndt SI, Siddiq A et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum. Mol. Genet. 20(19), 3867-3875 (2011
32. Takata R, Akamatsu S, Kubo M et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat. Genet. 42(9), 751-754 (2010
33. Haiman CA, Chen GK, Blot WJ et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat. Genet. 43(6), 570-573 (2011
34. Sun J, Zheng SL, Wiklund F et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at17q12. Nat. Genet. 40(10), 1153-1155 (2008
35. Gudmundsson J, Sulem P, Steinthorsdottir V et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against Type 2 diabetes. Nat. Genet. 39(8), 977-983 (2007
36. Gudmundsson J, Sulem P, Gudbjartsson DF et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat. Genet. 41(10), 1122-1126 (2009
37. Amin Al Olama A, Kote-Jarai Z, Schumacher FR et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum. Mol. Genet. 22(2), 408-415 (2013
38. Hsu FC, Sun J, Wiklund F et al. A novel prostate cancer susceptibility locus at 19q13. Cancer Res. 69(7), 2720-2723 (2009
39. Grisanzio C, Werner L, Takeda D et al. Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc. Natl Acad. Sci. USA 109(28), 11252-11257 (2012
40. Fitzgerald LM, Zhang X, Kolb S et al. Investigation of the relationship between prostate cancer and MSMB and NCOA4 genetic variants and protein expression. Hum. Mutat. 34(1), 149-156 (2013
41. Goh CL, Saunders EJ, Leongamornlert DA et al. Clinical implications of family history of prostate cancer and genetic risk single nucleotide polymorphism (SNP) profiles in an active surveillance cohort. BJU Int. 112(5), 666-673 (2013
42. The AceView genes. www.ncbi.nlm.nih.gov/IEB/Research/Acembly
43. Ahmadiyeh N, Pomerantz MM, Grisanzio C et al. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc. Natl Acad. Sci. USA 107(21), 9742-9746 (2010
44. Whitaker HC, Kote-Jarai Z, Ross-Adams H et al. The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. PLoS ONE 5(10), e13363 (2010
45. Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target. Prostate 70(3), 333-340 (2010
46. Cramer S. Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels. J. Natl Cancer Inst. 95(14), 1044-1053 (2003
47. Kote-Jarai Z, Saunders EJ, Leongamornlert DA et al. Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum. Mol. Genet. 22(12), 2520-2528 (2013
48. Theodorou V, Boer M, Weigelt B, Jonkers J, Van Der Valk M, Hilkens J. Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas. Oncogene 23(36), 6047-6055 (2004
49. Thomson AA, Cunha GR. Prostatic growth and development are regulated by FGF10. Development 126(16), 3693-3701 (1999
50. Szarvas T, Becker M, Vom Dorp F et al. Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. Int. J. Cancer 128(6), 1486-1492 (2011
51. Thomas G, Jacobs KB, Kraft P et al. A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat. Genet. 41(5), 579-584 (2009
52. Edwards SM, Kote-Jarai Z, Meitz J et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am. J. Hum. Genet. 72(1), 1-12 (2003
53. Kote-Jarai Z, Leongamornlert D, Saunders E et al. BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. Br. J. Cancer 105(8), 1230-1234 (2011
54. Tryggvadottir L, Vidarsdottir L, Thorgeirsson T et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J. Natl Cancer Inst. 99(12), 929-935 (2007
55. Gallagher DJ, Gaudet MM, Pal P et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin. Cancer Res. 16(7), 2115-2121 (2010
56. Castro E, Goh C, Olmos D et al. Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. J. Clin. Oncol. 31(14), 1748-1757 (2013
57. Leongamornlert D, Mahmud N, Tymrakiewicz M et al. Germline BRCA1 mutations increase prostate cancer risk. Br. J. Cancer 106(10), 1697-1701 (2012
58. Watson P, Riley B. The tumor spectrum in the Lynch syndrome. Fam. Cancer 4(3), 245-248 (2005
59. Engel C, Loeffler M, Steinke V et al. Risks of less common cancers in proven mutation carriers with Lynch syndrome. J. Clin. Oncol. 30(35), 4409-4415 (2012
60. Grindedal EM, Moller P, Eeles R et al. Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiol. Biomarkers Prev. 18(9), 2460-2467 (2009
61. Barrow E, Robinson L, Alduaij W et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin. Genet. 75(2), 141-149 (2009
62. Raymond VM, Mukherjee B, Wang F et al. Elevated risk of prostate cancer among men with Lynch syndrome. J. Clin. Oncol. 31(14), 1713-1718 (2013
63. Lanza G, Gafà R, Santini A, Maestri I, Guerzoni L, Cavazzini L. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and Iii colorectal cancer patients. J. Clin. Oncol. 24(15), 2359-2367 (2006
64. Goodman FR, Scambler PJ. Human HOX gene mutations. Clin. Genet. 59(1), 1-11 (2001
65. Economides KD, Capecchi MR. Hoxb13 is required for normal differentiation and secretory function of the ventral prostate. Development 130(10), 2061-2069 (2003
66. Jung C, Kim RS, Zhang HJ, Lee SJ, Jeng MH. HOXB13 induces growth suppression of prostate cancer cells as a repressor of hormone-activated androgen receptor signaling. Cancer Res. 64(24), 9185-9192 (2004
67. Norris JD, Chang CY, Wittmann BM et al. The homeodomain protein HOXB13 regulates the cellular response to androgens. Mol. Cell 36(3), 405-416 (2009
68. Lange EM, Robbins CM, Gillanders EM et al. Fine-mapping the putative chromosome 17q21-22 prostate cancer susceptibility gene to a 10 cM region based on linkage analysis. Hum. Genet. 121(1), 49-55 (2007
69. MacInnis RJ, Severi G, Baglietto L et al. Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PLoS ONE 8(2), e54727 (2013
70. Lin X, Qu L, Chen Z et al. A novel germline mutation in HOXB13 is associated with prostate cancer risk in Chinese men. Prostate 73(2), 169-175 (2013
71. Shang Z, Zhu S, Zhang H, Li L, Niu Y. Germline homeobox B13 (HOXB13) G84E mutation and prostate cancer risk in European descendants: a meta-analysis of 24 213 cases and 73 631 controls. Eur. Urol. (2013
72. Huang H, Cai B. G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis. Tumour Biol. 35(2), 1177-1182 (2013
73. Barnett GC, Coles CE, Elliott RM et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. Lancet Oncol. 13(1), 65-77 (2012
74. Hirata H, Hinoda Y, Kikuno N et al. Bcl2-938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. J. Urol. 181(4), 1907-1912 (2009
75. Jaboin JJ, Hwang M, Lopater Z et al. The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 79(5), 1330-1335 (2011
76. Morote J, Del Amo J, Borque A et al. Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms. J. Urol. 184(2), 506-511 (2010
77. Lindstrom S, Adami HO, Balter KA et al. Inherited variation in hormone-regulating genes and prostate cancer survival. Clin. Cancer Res. 13(17), 5156-5161 (2007
78. Maki HE, Waltering KK, Wallen MJ et al. Screening of genetic and expression alterations of SRC1 gene in prostate cancer. Prostate 66(13), 1391-1398 (2006
79. Holt SK, Karyadi DM, Kwon EM, Stanford JL, Nelson PS, Ostrander EA. Association of megalin genetic polymorphisms with prostate cancer risk and prognosis. Clin. Cancer Res. 14(12), 3823-3831 (2008
80. Lin K, Croswell JM, Koenig H, Lam C, Maltz A; U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews. Prostate-Specific Antigen-Based Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force [Internet]. Agency for Healthcare Research and Quality, Rockville, MD, USA, 10-12 (2011).www. uspreventiveservicestaskforce.org/prostatecancerscreening.htm
81. Andriole GL, Crawford ED, Grubb RL 3rd et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360(13), 1310-1319 (2009
82. Andriole GL, Crawford ED, Grubb RL 3rd et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl Cancer Inst. 104(2), 125-132 (2012
83. Crawford ED, Grubb R, 3rd, Black A et al. Comorbidity and mortality results from a randomized prostate cancer screening trial. J. Clin. Oncol. 29(4), 355-361 (2011
84. Schroder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360(13), 1320-1328 (2009
85. Hugosson J, Carlsson S, Aus G et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11(8), 725-732 (2010
86. Welch HG, Albertsen PC. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J. Natl Cancer Inst. 101(19), 1325-1329 (2009
87. Timothy J Wilt MB. Radical prostatectomy vs observation for localised prostate cancer. N. Engl. J. Med. 367(3), 203-213 (2012
88. Basch E, Oliver TK, Vickers A et al. Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology provisional clinical opinion. J. Clin. Oncol. 30(24), 3020-3025 (2012
89. Force US Preventive Services Task Force. Screening for Prostate Cancer (2012). www.uspreventiveservicestaskforce.org/prostatecancerscreening.htm
90. Mitra AV, Bancroft EK, Eeles RA. A review of targeted screening for prostate cancer: introducing the IMPACT study. BJU Int. 99, 1350-1355 (2006
91. Impact: IMPACT (the Identification of Men with a genetic Predisposition to Prostate Cancer: Targeted screening in BRCA1/2 mutation carriers and controls). www.impact-study.co.uk
92. Mitra AV, Bancroft EK, Barbachano Y et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int. 107(1), 28-39 (2011
93. Eeles R, Goh C, Castro E et al. The genetic epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol. 11(1), 18-31 (2014
94. MacInnis RJ, Antoniou AC, Eeles RA et al. A risk prediction algorithm based on family history and common genetic variants: application to prostate cancer with potential clinical impact. Genet. Epidemiol. 35(6), 549-556 (2011). calculate PrCa risk using family history and single nucleotide polymorphism profiling
95. Zheng SL, Sun J, Wiklund F et al. Cumulative association of five genetic variants with prostate cancer. N. Engl. J. Med. 358(9), 910-919 (2008
96. Janssens AC, Ioannidis JP, Bedrosian S et al. Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration. Eur. J. Epidemiol. 26(4), 313-337 (2011
97. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur. J. Clin. Invest. 40(1), 35-53 (2010
98. Killick E, Bancroft E, Kote-Jarai Z, Eeles R. Beyond prostate-specific antigen-future biomarkers for the early detection and management of prostate cancer. Clin. Oncol. 24(8), 545-555 (2012
99. Perner S, Schmidt FH, Hofer MD, Kuefer R, Rubin M. [TMPRSS2-ETS gene fusion in prostate cancer]. Urologe A 46(7), 754-760 (2007
100. Fernandez-Serra A, Rubio L, Calatrava A et al. Molecular characterization and clinical impact of TMPRSS2-ERG rearrangement on prostate cancer: comparison between FISH and RT-PCR. BioMed Res. Int. 465179 (2013) (2013
101. Weinmann S, Van Den Eeden SK, Haque R et al. Immunohistochemical expression of ERG in the molecular epidemiology of fatal prostate cancer Study. Prostate 73(13), 1371-1377 (2013
102. Tomlins SA, Aubin SM, Siddiqui J et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci. Trans. Med. 3(94), 94ra72 (2011
103. Bussemakers MJG. A new prostate specific gene, highly overexpressed in prostate cancer. Cancer Res. 59, 5975-5979 (1999
104. Hessels D. DD3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 44, 8-16 (2003
105. Deras IL, Aubin SM, Blase A et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J. Urol. 179(4), 1587-1592 (2008
106. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J. Urol. 179(5), 1804-1809; discussion 1809-1810 (2008
107. Haese A, De La Taille A, Van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur. Urol. 54(5), 1081-1088 (2008
108. Lin DW, Newcomb LF, Brown EC et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin. Cancer Res. 19(9), 2442-2450 (2013
109. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231), 910-914 (2009
110. Koutros S. Prospective evaluation of serum sarcosine and risk of prostate cancer in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Carcinogenesis 73(13), 1371-1377 (2013
111. Castro E, Eeles R. The role of BRCA1 and BRCA2 in prostate cancer. Asian J. Androl. 14(3), 409-414 (2012
112. Eeles R. The genetic epidemiology of prostate cancer and its clinical implications. Nat. Rev. Urol. 11(1), 18-31 (2013
113. Oyama N, Akino H, Kanamaru H et al. 11C-acetate PET imaging of prostate cancer. J. Nucl. Med. 43(2), 181-186 (2002
114. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J. Nucl. Med. 39(6), 990-995 (1998
115. Rinnab L, Mottaghy FM, Blumstein NM et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int. 100(4), 786-793 (2007
116. Cimitan M, Bortolus R, Morassut S et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur. J. Nucl. Med. Mol. Imaging 33(12), 1387-1398 (2006
117. Practical: PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome) (2008). www.srl.cam.ac.uk/ consortia/practical/index.html
118. Health NIO. ELLIPSE (Elucidating Loci Involved in Prostate Cancer Susceptibility) (2010). http://epi.grants.cancer.gov/pgwas/personnel. html#ellipse
119. Cogs: Collaborative Oncological Gene-environment Study (2009). www.cogseu.org Future
120. Hall P. Current knowledge and tomorrows challenges of breast, ovarian and prostate cancer genetics. J. Intern. Med. 217, 318-320 (2012
121. Li N, Stephens M. Modeling linkage disequilibrium and identifying recombination hotspots using single-nucleotide polymorphism data. Genetics 165(4), 2213-2233 (2003
122. Browning SR. Missing data imputation and haplotype phase inference for genome-wide association studies. Hum. Genet. 124(5), 439-450 (2008
123. A catalog of published genome-wide association studies. www.gwascentral.org/studies
124. Castro E, Goh CL, Eeles R. Prostate cancer screening in BRCA and Lynch syndrome mutation carriers. Am. Soc. Clin. Oncol. Educ. Book doi:10.1200/EdBook-AM.2013.33.e50 (2013) (Epub ahead of print
125. Kirkegaard P, Vedsted P, Edwards A, Fenger-Gron M, Bro F. A cluster-randomised, parallel group, controlled intervention study of genetic prostate cancer risk assessment and use of PSA tests in general practice-the ProCaRis study: study protocol. BMJ Open 3(3), e002452 (2013).